Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 275, Issue 6 44-6, 1998, Pages

  Scott, Jeremy A ^a,c   Weir, M Lynn ^b,c,d   Wilson, Sylvia M ^b,c   Xuan, Jim W ^b,c   Chambers, Ann F ^b,c   McCormack, David G ^a,c  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Endotoxin; Lipopolysaccharide; Sepsis

Indexed keywords

ARGININE; CITRULLINE; LIPOPOLYSACCHARIDE; NITRIC OXIDE SYNTHASE; OSTEOPONTIN;

AMINO ACID SEQUENCE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INDUCTION; ENZYME INHIBITION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SEPSIS; THORACIC AORTA;

EID: 33750854544     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1998.275.6.h2258     Document Type: Article

References (44)

1. Behrend, E. I., A. M. Craig, S. M. Wilson, D. T. Denhardt, and A. F. Chambers. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res. 54: 832-837, 1994.
2. Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.
3. Denhardt, D. T., and A. F. Chambers. Overcoming obstacles to metastasis-defences against host defences: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J. Cell. Biochem. 56: 48-51, 1994.
4. Denhardt, D. T., and X. Guo. Osteopontin: a protein with diverse functions. FASEB J. 7: 1475-1482, 1993.
5. Edwards, D. R., and D. T. Denhardt. A study of mitochondrial and nuclear transcription with cloned cDNA probes: changes in the relative abundance of mitochondrial transcripts after stimulation of quiescent mouse fibroblasts. Exp. Cell Res. 157: 127-143, 1985.
6. Eissa, N. T., J. W. Yuan, C. M. Haggerty, E. K. Choo, C. D. Palmer, and J. Moss. Characterization of a splice variant of human inducible nitric oxide synthase: a domain encoded by exons 8-9 is critical for dimerization (Abstract). Am. J. Respir. Crit. Care Med. 157: A514, 1998.
7. Feng, B., E. E. Rollo, and D. T. Denhardt. Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by targeted ribozyme. Clin. Exp. Metastasis 13: 453-462, 1995.
8. Gardner, H. A. R., B. Berse, and D. R. Senger. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 9: 2321-2326, 1994.
9. Giachelli, C. M., N. Bae, M. Almeida, and D. T. Denhardt. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Invest. 92: 1686-1696, 1993.
10. Giachelli, C. M., S. M. Schwartz, and L. Liaw. Molecular and cellular biology of osteopontin: potential role in cardiovascular disease. Trends Cardiovasc. Med. 5: 88-95, 1995.
11. Hibbs, J. B., Jr., R. R. Taintor, and Z. Zavrin. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 235: 473-476, 1987.
12. Hultgardh-Nilsson, A., C. Lovdahl, K. Blomgren, B. Kallin, and J. Thyberg. Expression of phenotype- and proliferation-related genes in rat aortic smooth muscle cells in primary culture. Cardiovasc. Res. 34: 418-430, 1997.
13. Hwang, S.-M., C. A. Lopez, D. E. Heck, C. R. Gardner, D. L. Laskin, J. D. Laskin, and D. T. Denhardt. Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J. Biol. Chem. 269: 711-715, 1994.
14. Hynes, R. O. Integrin: versatility, modulation and signalling in cell adhesion. Cell 69: 11-25, 1992.
15. Juliano, R. L. Signal transduction by integrins and its role in the regulation of tumor growth. Cancer Metastasis Rev. 13: 25-30, 1994.
16. Kanwar, S., and P. Kubes. Nitric oxide is an antiadhesive molecular for leukocytes. New Horizons 3: 93-104, 1995.
17. Knowles, R. G., M. Salter, S. L. Brooks, and S. Moncada. Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem. Biophys. Res. Commun. 172: 1042-1048, 1990.
18. Kubes, P., S. Kanwar, S.-F. Niu, and J. P. Gaboury. Nitric oxide synthesis inhibition induces leukocyte adhesion via superoxide and mast cells. FASEB J. 7: 1293-1299, 1993.
19. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
20. Liaw, L., M. Almeida, C. E. Hart, S. M. Schwartz, and C. M. Giachelli. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ. Res. 74: 214-224, 1994.
21. 3-integrin are coordinately expressed in regenerating endothelium in vivo and stimulate RGD-dependent endothelial migration in vitro. Circ. Res. 77: 665-672, 1995.
22. Liu, S. F., I. M. Adcock, R. W. Old, P. J. Barnes, and T. W. Evans. Differential regulation of the constitutive and inducible nitric oxide synthase mRNA by lipopolysaccharide treatment in vivo in the rat. Crit. Care Med. 24: 1219-1225, 1996.
23. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
24. Marietta, M. A. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 78: 927-930, 1994.
25. Meyer, J., L. D. Traber, S. Nelson, C. W. Lentz, H. Nakazawa, D. N. Herndon, H. Noda, and D. L. Traber. Reversal of hyperdynamic response to continuous endotoxin administration by inhibition of NO synthesis. J. Appl. Physiol. 73: 324-328, 1992.
26. Nathan, C., and Q.-W. Xie. Nitric oxide synthases: roles, tolls and controls. Cell 78: 915-918, 1994.
27. Newman, C. M., B. C. Bruun, P. K. Mistry, P. L. Weissberg, and C. M. Shanahan. High expression of Osteopontin mRNA in human macrophages but not human vascular smooth muscle cells in culture. Ann. NY Acad. Sci. 760: 381-381, 1995.
28. Oates, A. J., R. Barraclough, and P. S. Rudland. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogens 13: 97-104, 1996.
29. Pang, S. C., and S. L. Venance. Cultured smooth muscle approach in the study of hypertension. Can. J. Physiol. Pharmacol. 70: 573-579, 1992.
30. Parrish, A. R., and K. S. Ramos. Differential processing of osteopontin characterizes the proliferative vascular smooth muscle cell phenotype induced by allylamine. J. Cell. Biochem. 65: 267-275, 1997.
31. Patarca, T., R. A. Saavedra, and H. Cantor. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit. Rev. Immunol. 13: 225-246, 1993.
32. Peterson, G. L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 83: 346-356, 1977.
33. Radomski, M. W., R. M. J. Palmer, and S. Moncada. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad. Sci. USA 87: 10043-10047, 1990.
34. Rees, D. D., S. Cellek, R. M. J. Palmer, and S. Moncada. Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem. Biophys. Res. Commun. 173: 541-547, 1990.
35. Rollo, E. E., and D. T. Denhardt. Differential effects of osteopontin on the cytotoxic activity of macrophages from young and old mice. Immunology 88: 642-647, 1996.
36. Rollo, E. E., D. L. Laskin, and D. T. Denhardt. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J. Leukoc. Biol. 60: 397-404, 1996.
37. Schmidt, H. H. H. W., and U. Walter. NO at work. Cell 78: 919-925, 1994.
38. Scott, J. A., M. Machoun, and D. G. McCormack. Inducible nitric oxide synthase and vascular reactivity in rat thoracic aorta: effect of aminoguanidine. J. Appl. Physiol. 80: 271-277, 1996.
39. Senger, D. R., C. A. Perruzzi, and A. Papadoupoulos. Elevated expression of secreted phosphoprotein 1 (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res. 9: 1291-1300, 1989.
40. Singh, K., J.-L. Balligand, T. A. Fischer, T. W. Smith, and R. A. Kelly. Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells - role in regulation of inducible nitric oxide synthase. J. Biol. Chem. 270: 28471-28478, 1995.
41. Weber, G. R, S. Ashkar, M. J. Glimcher, and H. Cantor. Receptor-ligand interaction between CD44 and osteopontin (Eta1). Science 271: 509-512, 1996.
42. Xuan, J.-W., C. Hota, and A. F. Chambers. Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J. Cell. Biochem. 54: 247-255, 1994.
43. Xuan, J.-W., C. Hota, Y. Shigeyama, J. A. D'Errico, M. J. Somerman, and A. F. Chambers. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J. Cell. Biochem. 57: 680-690, 1995.
44. Yoshizumi, M., M. A. Perella, J. C. Burnett, Jr., and M.-E. Lee. Tumor necrosis factor down-regulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ. Res. 73: 205-209, 1993.